Stoke Therapeutics (STOK) Research & Development (2018 - 2026)

Stoke Therapeutics' Research & Development history runs 9 years deep, the most recent figure standing at $39.7 million for Q1 2026.

• On a quarterly basis, Research & Development rose 21.41% year-over-year to $39.7 million in Q1 2026; TTM through Mar 2026 was $144.9 million, a 45.74% increase from a year earlier, with the FY2025 full-year figure at $137.9 million, up 54.74% from the prior year.
• Research & Development eased to $39.7 million in Q1 2026 per STOK's latest filing, from $41.7 million in the prior quarter.
• Across five years, Research & Development topped out at $41.7 million in Q4 2025 and bottomed at $18.3 million in Q1 2022.
• The 5-year median for Research & Development is $21.8 million (2023), against an average of $25.1 million.
• Across the five-year window, Research & Development surged 84.7% in 2022 and climbed 0.81% in 2023, its largest moves.
• Year by year, Research & Development stood at $21.1 million in 2022, then grew by 3.41% to $21.8 million in 2023, then gained by 7.55% to $23.4 million in 2024, then jumped by 78.01% to $41.7 million in 2025, then retreated by 4.85% to $39.7 million in 2026.
• Per Business Quant, the three latest STOK Research & Development figures stand at $39.7 million (Q1 2026), $41.7 million (Q4 2025), and $37.7 million (Q3 2025).